Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn’s Disease
- 1 March 2023
- journal article
- letter
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 21 (3) , 838-840.e2
Abstract
No abstract availableFunding Information
- Leona M and Harry B Helmsley Charitable Trust
- Research Foundation Flanders
This publication has 10 references indexed in Scilit:
- Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical RemissionClinical Gastroenterology and Hepatology, 2021
- Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studiesExpert Opinion on Biological Therapy, 2019
- Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2019
- Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission RatesJournal of Crohn's and Colitis, 2019
- Influence of early adalimumab serum levels on immunogenicity and long‐term outcome of anti‐TNF naive Crohn's disease patients: the usefulness of rapid testingAlimentary Pharmacology & Therapeutics, 2018
- Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's DiseaseGastroenterology, 2018
- Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2017
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseNew England Journal of Medicine, 2016
- Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2014
- Discovery and mechanism of ustekinumabmAbs, 2011